182 related articles for article (PubMed ID: 21419438)
1. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer.
Whitson JM; Porten SP; Hilton JF; Cowan JE; Perez N; Cooperberg MR; Greene KL; Meng MV; Simko JP; Shinohara K; Carroll PR
J Urol; 2011 May; 185(5):1656-60. PubMed ID: 21419438
[TBL] [Abstract][Full Text] [Related]
2. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.
San Francisco IF; Werner L; Regan MM; Garnick MB; Bubley G; DeWolf WC
J Urol; 2011 Feb; 185(2):471-6. PubMed ID: 21167525
[TBL] [Abstract][Full Text] [Related]
3. Repeat prostate biopsies predict location of index cancer in an active surveillance cohort.
Tseng KS; Landis P; Brimo F; Partin AW; Epstein JI; Carter HB
BJU Int; 2011 Nov; 108(9):1415-20. PubMed ID: 21443654
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
[TBL] [Abstract][Full Text] [Related]
5. Re: Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
Singh A
Can J Urol; 2009 Jun; 16(3):4659. PubMed ID: 19497173
[No Abstract] [Full Text] [Related]
6. Staging saturation biopsy in patients with prostate cancer on active surveillance protocol.
Abouassaly R; Lane BR; Jones JS
Urology; 2008 Apr; 71(4):573-7. PubMed ID: 18387385
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
Roobol MJ; Kranse R; de Koning HJ; Schröder FH
Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
[TBL] [Abstract][Full Text] [Related]
8. PSA kinetics: no substitute for annual biopsy in prostate cancer surveillance?
Schmidt C
J Natl Cancer Inst; 2010 Oct; 102(20):1533-5. PubMed ID: 20935269
[No Abstract] [Full Text] [Related]
9. The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC).
Roobol MJ; Zappa M; Määttänen L; Ciatto S
Prostate; 2007 Mar; 67(4):439-46. PubMed ID: 17192912
[TBL] [Abstract][Full Text] [Related]
10. Can the number of cores with high-grade prostate intraepithelial neoplasia predict cancer in men who undergo repeat biopsy?
Naya Y; Ayala AG; Tamboli P; Babaian RJ
Urology; 2004 Mar; 63(3):503-8. PubMed ID: 15028446
[TBL] [Abstract][Full Text] [Related]
11. Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
Kumar A; Godoy G; Taneja SS
Can J Urol; 2009 Jun; 16(3):4655-9. PubMed ID: 19497172
[TBL] [Abstract][Full Text] [Related]
12. Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL.
Nakano Y; Okamura K; Takamura S; Okamoto N; Narishima M; Yoshino Y; Hattori R; Ono Y; Ohshima S; Nagasaka T
Int J Urol; 2005 Aug; 12(8):721-7. PubMed ID: 16174045
[TBL] [Abstract][Full Text] [Related]
13. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database.
Scales CD; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL; Freedland SJ;
J Urol; 2007 Oct; 178(4 Pt 1):1249-52. PubMed ID: 17698131
[TBL] [Abstract][Full Text] [Related]
14. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
[TBL] [Abstract][Full Text] [Related]
15. [The density of prostate specific antigen of the transition zone as an early predictor of prostate cancer].
Topuzov ME; Prialukhin AE; Zhivov AV; Plekhanov AIu
Vestn Khir Im I I Grek; 2008; 167(6):119-21. PubMed ID: 19241832
[TBL] [Abstract][Full Text] [Related]
16. Modeling prostate specific antigen kinetics in patients on active surveillance.
Zhang L; Loblaw A; Klotz L
J Urol; 2006 Oct; 176(4 Pt 1):1392-7; discussion 1397-8. PubMed ID: 16952640
[TBL] [Abstract][Full Text] [Related]
17. Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era.
Ercole B; Marietti SR; Fine J; Albertsen PC
J Urol; 2008 Oct; 180(4):1336-9; discussion 1340-1. PubMed ID: 18707696
[TBL] [Abstract][Full Text] [Related]
18. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program.
Tosoian JJ; Loeb S; Kettermann A; Landis P; Elliot DJ; Epstein JI; Partin AW; Carter HB; Sokoll LJ
J Urol; 2010 Feb; 183(2):534-8. PubMed ID: 20006883
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
Krakowsky Y; Loblaw A; Klotz L
J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure.
D'Amico AV; Cote K; Loffredo M; Renshaw AA; Chen MH
J Urol; 2003 Apr; 169(4):1320-4. PubMed ID: 12629352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]